Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0BXOQG
ADC Name	h15H3-gluc-MMAE
Synonyms	h15H3 gluc MMAE Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Pancreatic cancer [ICD11:2C10] Investigative
Drug-to-Antibody Ratio	8
	3D MOL	2D MOL
Antibody Name	Anti-ITGA5 mAb h15H3		Antibody Info
Antigen Name	Integrin alpha-5 (ITGA5)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Quaternary ammonium linker Gluc		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Gluc-MMAE

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 88.93	%	Detroit 562 cells	Pharyngeal squamous cell carcinoma
Tumor Growth Inhibition value (TGI)	≈ 88.94	%	HPAF-II cells	Pancreatic ductal adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.93% (Day 29)	Positive ITGA5 expression (ITGA5 +++/++)
Method Description	Mice were administered a single 3 mg/kg IP dose once tumors reached 100 mm³ and tumor size was measured at various time points.
In Vivo Model	Detroit 562 CDX model
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.94% (Day 25)	Positive ITGA5 expression (ITGA5 +++/++)
Method Description	Mice were administered a single 3 mg/kg IP dose once tumors reached 100 mm³ and tumor size was measured at various time points.
In Vivo Model	HPAF-II CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	HPAF-II cells		CVCL_0313

References

Ref 1	A coiled-coil masking domain for selective activation of therapeutic antibodies. Nat Biotechnol. 2019 Jul;37(7):761-765. doi: 10.1038/s41587-019-0135-x. Epub 2019 May 27.